From the Food and Drug Administration

JAMA. 1992 May 13;267(18):2445. doi: 10.1001/jama.267.18.2445.
No abstract available

MeSH terms

  • 2-Chloroadenosine / analogs & derivatives
  • 2-Chloroadenosine / therapeutic use
  • Angiotensin-Converting Enzyme Inhibitors / adverse effects*
  • Antineoplastic Agents / therapeutic use
  • Antitubercular Agents / therapeutic use
  • Cladribine
  • Deoxyadenosines / therapeutic use
  • Drugs, Investigational*
  • Equipment and Supplies*
  • Fetus / drug effects*
  • Humans
  • Leukemia, Hairy Cell / drug therapy
  • Mycobacterium avium-intracellulare Infection / drug therapy
  • Product Surveillance, Postmarketing*
  • Rifabutin
  • Rifamycins / therapeutic use
  • United States
  • United States Food and Drug Administration

Substances

  • Angiotensin-Converting Enzyme Inhibitors
  • Antineoplastic Agents
  • Antitubercular Agents
  • Deoxyadenosines
  • Drugs, Investigational
  • Rifamycins
  • 2-Chloroadenosine
  • Rifabutin
  • Cladribine